Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.84 |
| ▸ | LCK | P06239 | 4/20 | 0.84 |
| ▸ | LYN | P07948 | 2/20 | 0.84 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.78 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | KDR | P35968 | 1/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 3/20 | 0.68 |
| ▸ | ITK | Q08881 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | YES1 | P07947 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | FGR | P09769 | 1/20 | 0.68 |
| ▸ | FER | P16591 | 1/20 | 0.68 |
| ▸ | CSK | P41240 | 1/20 | 0.68 |
| ▸ | TEC | P42680 | 1/20 | 0.68 |
| ▸ | BLK | P51451 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15915382 | 1.00 | BTK (0.84) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL30586962 | 0.91 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL6431516 | 0.91 | BTK (1.00) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL29441896 | 0.91 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL7001715 | 0.91 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243244 | 0.91 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243281 | 0.91 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL18645940 | 0.90 | BTK (0.78) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL17713980 | 0.90 | BTK (0.98) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL5803102 | 0.88 | BTK (0.82) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248979-B1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INST PHYSICAL SCI CAS (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3248979-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | Hefei Institutes of Physical Sicence, Chinese Academy of Sciences (CN) | 2017-11-29 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| WO-2016115869-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2016-07-28 | — | — | WO | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2532235-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532234-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2529621-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2529622-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2530083-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2443929-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2201840-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | BTK 32/4885LCK 114/4885LYN 145/4885 |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | BTK 5/4885LCK 14/4885LYN 24/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885LCK 148/4885LYN 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.